Sedana Medical AB (publ) (SEDANA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to today's Finwire presentation with Sedana Medical. After the presentation, there will be a question and answer session. So if you have any questions, you can submit them in English using the form on the right. With that said, I'll hand the floor to you. Please go ahead. Thank you for the introduction. Warm welcome to our Q2 report 2026. I'm here with our new CFO, Michael Haag, who will introduce himself and speak about our financials in just a few minutes. Peter Sackey, our Chief Medical Officer, who's usually with us, is not here today as he's traveling in the U.S. onboarding the next large hospital into our Early Access Program. So let's talk about the second quarter. What stands out, of course, is the NDA submission in June, a huge milestone after years of work on our U.S. clinical and regulatory program. So our biggest growth opportunity, the United States has moved another step closer. At the same time, we managed to further improve profitability, even though sales on the group level were flat versus a very strong Q2 last year. So let's jump right into the highlights on page three. Thank you. Structured around our three priorities. So growing sales in our core markets, reaching profitability and our exciting US journey. Q2 net sales were 49 million SEK, which is flat compared to last year at constant exchange rates. If we look only at the core business, so excluding the contract manufacturing sales from our factory in Malaysia, sales were slightly up by 1%. We had a delayed shipment to our contract manufacturing customer that shifted from June into July. So it's actually the contract manufacturing business that pulls us down just slightly on the group level, but that's a pure timing effect. Still, this flattish development looks a bit underwh...